Cormed Inc – FDA CRL

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to CorMedix Inc. regarding their New Drug Application (NDA 214520) for taurolidine and heparin catheter lock solution. This decision, following a review of the application and its amendments, indicates that the application cannot be approved in its current form.

A key issue identified stemmed from recent inspections of the manufacturing facilities, where deficiencies were observed. Resolution of these product quality and facility-related concerns is a prerequisite for approval. Additionally, the FDA requires significant revisions to the proposed prescribing information and carton and container labeling to ensure compliance with regulatory content and format requirements.

The proposed proprietary name, "Defencath," was deemed unacceptable due to potential confusion with another product. CorMedix Inc. needs to submit a new request for an alternate proprietary name review.

Under the Federal Food, Drug, and Cosmetic Act, CorMedix Inc. must also provide a comprehensive safety update upon resubmission. This includes presenting new and updated safety data from all studies, detailing significant changes, comparing adverse event frequencies, providing case reports for deaths or serious adverse events, and summarizing worldwide safety experience. Furthermore, discrepancies in listed manufacturing and testing facilities supporting the application need to be clarified and updated.

All these deficiencies must be satisfactorily addressed before the NDA can be reconsidered for approval.